Aims Previously published pharmacokinetic (PK) models for sunitinib and its active
metabolite SU 12662 were based on a limited dataset or lacked important elements such as …

Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for
advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal …

Using physiologically based pharmacokinetic (PBPK) modeling and simulations, this study
estimated the exposure of sunitinib and its active metabolite SU012662 in pediatric patients …

Abstract Background and Objective The wide inter-patient variability in drug exposure partly
explains the toxicity and efficacy profile of sunitinib treatment. In this prospective study …

Purpose The safety profile of sunitinib in children, including the impact of sunitinib exposure
on safety endpoints, was assessed using population pharmacokinetic (PK) and …

Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore,
a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib …

ABSTRACT A rapid, selective, and sensitive liquid chromatography–tandem mass
spectrometry method was developed and validated for the simultaneous determination of …

Abstract Background and Objective Circadian rhythms may influence the pharmacokinetics
of drugs. This study aimed to elucidate whether the pharmacokinetics of the orally …

The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-
targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activities) was …

Background Fluoroquinolones are widely prescribed antibiotics. Ciprofloxacin is a well-
known inhibitor of cytochrome P450 CYP3A4 and causes numerous drug interactions that …